Beta-thalassemia future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Beta-thalassemia}} | {{Beta-thalassemia}} | ||
{{CMG}}; {{AE}} {{MHP}} | |||
==Overview== | |||
==Future or investigational therapies== | |||
Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
Revision as of 22:14, 21 August 2023
|
Beta-thalassemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Beta-thalassemia future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Beta-thalassemia future or investigational therapies |
|
Beta-thalassemia future or investigational therapies in the news |
|
Blogs on Beta-thalassemia future or investigational therapies |
|
Risk calculators and risk factors for Beta-thalassemia future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Hadipour, M.D.[2]
Overview
Future or investigational therapies
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing. [1]
References
- ↑ Coquerelle S, Ghardallou M, Rais S, Taupin P, Touzot F, Boquet L, Blanche S, Benaouadi S, Brice T, Tuchmann-Durand C, Ribeil JA, Magrin E, Lissillour E, Rochaix L, Cavazzana M, Durand-Zaleski I (June 2019). "Innovative Curative Treatment of Beta Thalassemia: Cost-Efficacy Analysis of Gene Therapy Versus Allogenic Hematopoietic Stem-Cell Transplantation". Hum Gene Ther. 30 (6): 753–761. doi:10.1089/hum.2018.178. PMID 30700149.